Claims for Patent: 7,658,945

Summary for Patent: 7,658,945

Title:	Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
Abstract:	The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present invention for treating sleep disorders such as insomnia are also provided.
Inventor(s):	Singh; Nikhilesh N. (Mill Valley, CA)
Assignee:	Transcept Pharmaceuticals, Inc. (Pt. Richmond, CA)
Application Number:	11/060,641
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,658,945
Patent Claims:	1. A method for treating insomnia, comprising the steps of: administering to a subject a solid pharmaceutical composition comprising zolpidem in an amount from about 1 mg to about 5 mg, a carbonate buffer, and a bicarbonate buffer, wherein zolpidem is absorbed across the subject's oral mucosa, wherein the carbonate buffer and bicarbonate buffer are present in a carbonate:bicarbonate weight ratio of about 1:1 to about 1:10 and raise the pH of saliva to a pH of about 7.8 or greater, and wherein at least 75% of the solid pharmaceutical composition dissolves within about 10 minutes or less within an oral cavity following administration. 2. The method of claim 1, wherein the solid pharmaceutical composition further comprises a binder and a disintegrating agent. 3. The method of claim 1, wherein the solid pharmaceutical composition dissolves within about 10 minutes or less within said oral cavity following administration. 4. The method of claim 1, wherein the solid pharmaceutical composition dissolves within about 1-3 minutes within said oral cavity following administration. 5. The method of claim 1, wherein the solid pharmaceutical composition dissolves within about 2-3 minutes within said oral cavity following administration. 6. The method of claim 1, wherein the solid pharmaceutical composition is administered sublingually. 7. The method of claim 1, wherein the oral mucosa is selected from the group consisting of sublingual mucosa, buccal mucosa, gingival mucosa, palatal mucosa, and lining of the lips. 8. The method of claim 1, wherein a mean peak plasma concentration of zolpidem between about 20 to about 100 ng/mL is produced within about 30 minutes. 9. The method of claim 1, wherein a therapeutically effective amount of zolpidem enters the bloodstream within about 30 minutes. 10. The method of claim 1, wherein the carbonate buffer and bicarbonate buffer are present in a carbonate:bicarbonate weight ratio of about 1:1 to about 1:5. 11. The method of claim 1, wherein the carbonate buffer and bicarbonate buffer are present in a carbonate:bicarbonate weight ratio of about 1:1 to about 1:2. 12. The method of claim 1, wherein the solid pharmaceutical composition is a lozenge. 13. The method of claim 1, wherein the solid pharmaceutical composition is a tablet. 14. A pharmaceutical composition comprising: about 1 mg to about 5 mg of zolpidem; a carbonate buffer; and a bicarbonate buffer, wherein the carbonate buffer and bicarbonate buffer are present in a carbonate:bicarbonate weight ratio of about 1:1 to about 1:10 and are adapted to raise the pH of saliva to about 7.8 or greater following administration, and wherein the solid pharmaceutical composition is adapted to dissolve by at least 75% within about 10 minutes or less within an oral cavity following administration. 15. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition is a solid pharmaceutical composition. 16. The pharmaceutical composition of claim 14, wherein the carbonate buffer and bicarbonate buffer are present in a carbonate:bicarbonate weight ratio of about 1:1 to about 1:5. 17. The pharmaceutical composition of claim 14, wherein the carbonate buffer and bicarbonate buffer are present in a carbonate:bicarbonate weight ratio of about 1:1 to about 1:2. 18. The pharmaceutical composition of claim 15, further comprising a binder and a disintegrating agent. 19. The pharmaceutical composition of claim 15, wherein the solid pharmaceutical composition is a lozenge. 20. The pharmaceutical composition of claim 15, wherein the solid pharmaceutical composition is a tablet. 21. The pharmaceutical composition of claim 14, wherein the carbonate buffer is selected from the group consisting of sodium carbonate, potassium carbonate, calcium carbonate, ammonium carbonate, and magnesium carbonate. 22. The pharmaceutical composition of claim 14, wherein the bicarbonate buffer is selected from the group consisting of sodium bicarbonate, potassium bicarbonate, calcium bicarbonate, ammonium bicarbonate, and magnesium bicarbonate. 23. The pharmaceutical composition of claim 14, wherein the bicarbonate buffer is dessicant-coated sodium bicarbonate. 24. The method of claim 1, wherein a therapeutically effective amount of zolpidem enters the bloodstream within about 20 minutes. 25. The pharmaceutical composition of claim 14, wherein the solid pharmaceutical composition is adapted to deliver a therapeutically effective amount of zolpidem into the bloodstream within about 30 minutes. 26. The pharmaceutical composition of claim 14, wherein the solid pharmaceutical composition is adapted to deliver a therapeutically effective amount of zolpidem into the bloodstream within about 20 minutes.